Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria